Newomics Inc., based in Berkeley, Calif., develops and commercializes mass spectrometry platforms for molecular detection applications. Its core offerings include the plug-and-play MnESI platform (MnESI source + M3 emitter) that interfaces with diverse mass spectrometry instruments and combines microflow LC robustness with nanospray ionization sensitivity. The company recently announced an MnESI-MS platform for clinical diagnostics and drug discovery and is developing a multinozzle emitter array (MEA) to increase sensitivity, robustness, and throughput, targeted for market in 2021. Newomics has been expanding its sales and marketing team, filling positions, and enhancing customer support while growing collaborations with major mass spectrometer vendors, including a second co-marketing agreement with Thermo Fisher Scientific. Customers and users include organizations such as Regeneron, which used Newomics’ M3 emitter in a recent publication. The company closed a $7.9 million Series B and plans to use proceeds to launch new products, grow commercial efforts, and expand vendor collaborations.

Total raised

$8M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2020